Although female participants represent more than 50 percent (n = 57,688,606) of the total number (115,377,213) included, considerable variability existed with the number of male (46,111,818), female (58,805,665), and unspecified (10,459,730) participants included among the journals, between U.S. domestic and international studies, and between single
vs multicenter studies.
A
multicenter, open - label trial of talimogene laherparepvec (T - VEC) plus pembrolizumab
vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB - IV melanoma.